Humacyte HUMA
NASDAQ HUMA
$0.41 +0.00 (+0.46%)
At close: Oct 22, 2026 · 4:00 PM EDT

Humacyte (HUMA) EBT Margin (2020 - 2026)

Updated

Humacyte (HUMA) reported EBT Margin of -7125.37% for Q2 2026, up 3319.81 percentage points from -10445.18% a year earlier but down 887.79 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) EBT Margin (2020 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Humacyte's EBT Margin came in at -5640.88%, up 8843.72 percentage points year-over-year; for FY2025, it was -5731.11%.

  • Five-year quarterly EBT Margin spans a low of -10445.18% in Q2 2025 and a high of -3507.57% in Q3 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -6237.58% (Q1 2026), -7157.60% (Q4 2025) and -3507.57% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 40.25%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 0.13%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 25.18%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -4.11%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 29.63%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 18.19%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 27.53%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -131.41%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -4.34%
10 Humacyte 96.48 Mn -101.96 Mn -825,000.00 -7,125.37%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7,125.37%
Mar 31, 2026 -6,237.58%
Dec 31, 2025 -7,157.60%
Sep 30, 2025 -3,507.57%
Jun 30, 2025 -10,445.18%
Mar 31, 2025 -4,939.65%
Sep 30, 2021 -9,022.41%
Sep 30, 2020 -1,943.11%
API Access

Humacyte EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY